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Abstract: Enzyme-assisted derivatization for sterol analysis (EADSA) is a technology designed to
enhance sensitivity and specificity for sterol analysis using electrospray ionization–mass spectrometry.
To date it has only been exploited on sterols with a 3β-hydroxy-5-ene or 3β-hydroxy-5α-hydrogen
structure, using bacterial cholesterol oxidase enzyme to convert the 3β-hydroxy group to a 3-oxo
group for subsequent derivatization with the positively charged Girard hydrazine reagents, or on
substrates with a native oxo group. Here we describe an extension of the technology by substituting
3α-hydroxysteroid dehydrogenase (3α-HSD) for cholesterol oxidase, making the method applicable
to sterols with a 3α-hydroxy-5β-hydrogen structure. The 3α-HSD enzyme works efficiently on
bile alcohols and bile acids with this stereochemistry. However, as found by others, derivatization
of the resultant 3-oxo group with a hydrazine reagent does not go to completion in the absence
of a conjugating double bond in the sterol structure. Nevertheless, Girard P derivatives of bile
alcohols and C27 acids give an intense molecular ion ([M]+) upon electrospray ionization and
informative fragmentation spectra. The method shows promise for analysis of bile alcohols and
3α-hydroxy-5β-C27-acids, enhancing the range of sterols that can be analyzed at high sensitivity in
sterolomic studies.
Keywords: bile alcohol; cholestanoic acid; oxysterol; sterolomics; enzyme-assisted derivatization;
electrospray ionization-mass spectrometry; Girard reagent
1. Introduction
Sterols represent one of the major classes of lipids found in living systems [1]. In mammals,
cholesterol represents the archetypal sterol. It is metabolized through a myriad of intermediates to
C21–18 steroids and to C24 bile acids [2–9]. For decades there was little interest in these intermediates,
however, in recent years the situation has changed with the realization that intermediates in bile
acid biosynthesis are ligands to nuclear receptors, including the liver X receptors (LXRs, NR1H3,
NR1H2) [10–13], farnesoid X receptor (FXR, NR1H4) [14], pregnane X receptor (PXR, also known as
xenobiotic sensing nuclear receptor, SXR, NR1I2) [15,16], RAR-related orphan receptor γt (RORγt,
NR1F3) [17], and estrogen receptors (ERs, NR3A1, NR3A2) [18]. They are also related to G
protein-coupled receptors (e.g., Epstein-Barr virus induced gene 2 (EBI2, GPR183) [19,20] and
smoothened (SMO, FZD11) [21,22]), and are involved in the regulation of cholesterol biosynthesis
by binding to INSIG1 (insulin induced gene 1) [23]. Cholesterol metabolites have traditionally
been analyzed by gas-chromatography-mass spectrometry (GC-MS) [3,4,6,24,25], however, liquid
chromatography (LC)-MS, is currently taking a dominant role in their analysis [5,26].
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Analysis of cholesterol metabolites is valuable for the diagnosis of rare inborn errors of metabolism,
and defects in bile acid and steroid synthesizing enzymes are efficiently characterized by LC-MS or
GC-MS analysis of plasma or urine [6,27–29]. By performing these analyses, unexpected metabolites
are identified, which are normally only minor components of the sterolome, but which are abundant
in the disease state [7–9]. When these unexpected metabolites are considered, it becomes evident that
the complexity of the sterolome is enormous. Sterolomics is one of the subdivisions of lipidomics,
however, in most lipidomic studies, sterols are underrepresented; this is because, other than cholesterol
and its esters, they are not abundant, and their ionization characteristics in positive-ion electrospray
ionization (ESI)-MS (the dominant ionization method in lipidomics) are poor [30,31]. To improve the
sensitivity for sterol analysis, many groups adopt a derivatization strategy where sterols are chemically
modified to improve their ionization characteristics [32–39].
One derivatization strategy that has lately become popular is enzyme-assisted derivatization
for sterol analysis (EADSA, Scheme 1) [8,9,12,13,17,40–47]. EADSA technology was designed to add
specificity and sensitivity to sterol analysis [40,44–46]. This is achieved by specifically targeting the
3β-hydroxy-5-ene or 3β-hydroxy-5α-hydrogen function in sterols and converting the 3β-hydroxy to a
3-oxo group with bacterial cholesterol oxidase from Brevibacterium or Streptomyces sp. [40,41]. Once
introduced, the 3-oxo group is derivatized with the positively charged Girard hydrazine reagent,
introducing a charge-tag to the target analyte and improving sensitivity in ESI-MS. A limitation of the
existing protocol is that it is not applicable to sterols with a 3α-hydroxy group. Here we describe how
this limitation is overcome for the analysis of bile alcohols and C27 bile acids with this stereochemistry.
The methodology is potentially applicable for C24 bile acids but requires further optimization to
achieve similar sensitivity as for C27 alcohols and acids.
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Scheme 1. Enzyme-assisted derivatization for sterol analysis (EASDA): (a) EADSA of the 3β-hydroxy-
5-ene function using cholesterol oxidase and [2H5] Girard P reagent ([2H5]GP); (b) derivatization of 
the 3-oxo-4-ene function with [2H0]GP; (c) EADSA of the 3α-hydroxy-5β-hydrogen function with 3α-
hydroxysteroid dehydrogenase (3α-HSD) and [2H0]GP. Derivatives with the [2H5]GP and [2H0]GP 
reagents can be combined and analyzed in a single LC-MS run. Other isotope-coded GP reagents have 
been synthesized to allow triplex analysis if required [45]. 
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cholic acid (3α,7α,12α-trihydroxy-5β-cholan-24-oic acid, BA-3α,7α,12α-triol) and 3α,7α,12α-
trihydroxy-5β-cholestan-26-oic acid (CA-3α,7α,12α-triol) as representative analytes, because unlike 
neutral sterols, C24 and C27 bile acids are readily ionized by ESI (negative-ion mode) and can be 
detected in LC-MS analysis in both their 3α-hydroxy or 3-oxo forms. To determine oxidization 
efficiency, the amounts of unoxidized (3α-hydroxy) and oxidized (3-oxo) acids were determined after 
different incubation periods and incorporated into equation (1). 
Oxidation efficiency (%) = amount oxidized/(amount oxidized + amount unoxidized) × 100% (1) 
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et al. have shown that an incubation time of 20 h leads to about 95% conversion of the 3α-hydroxy 
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2. Results
2.1. Oxidation Efficiency of 3α-Hydroxysteroid Dehydrogenase (3α-HSD)
The efficiency of oxidation of 3α-HSD towards 3α-hydroxy-5β-substrates was evaluated
using cholic acid (3α,7α,12α-trihydroxy-5β-cholan-24-oic acid, BA-3α,7α,12α-triol) and
3α,7α,12α-trihydroxy-5β-cholestan-26-oic acid (CA-3α,7α,12α-triol) as representative analytes,
because unlike neutral sterols, C24 and C27 bile acids are readily ionized by ESI (negative-ion mode)
and can be detected in LC-MS analysis in both their 3α-hydroxy or 3-oxo forms. To determine
oxidization efficiency, the amounts of unoxidized (3α-hydroxy) and oxidized (3-oxo) acids were
determined after different incubation periods and incorporated into Equation (1).
Oxidation efficiency (%) = amount oxidize /(amount oxidized + a o nt noxidized) × 100% (1)
Using similar reaction conditions to those employed in the current study (see Section 4.2.1),
Une et al. have shown that an incubation time of 20 h leads to about 95% conversion of the
3α-hydroxy group to the 3-one in cholic acid and in most bile alcohols [48]. We found that reducing
the incubation time to 14 h gave a similarly high yield (>95%) of product for CA-3α,7α,12α-triol
and cholic acid. Either incubation time, 14 h or 20 h, gave satisfactory results. In the current study,
similarly high efficiencies of oxidation (>95%) were found for both the glycine and taurine conjugates of
cholic acid and for unconjugated chenodeoxycholic (3α,7α-dihydroxy-5β-cholan-24-oic), deoxycholic
(3α,12α-dihydroxy-5β-cholan-24-oic) and lithocholic (3α-hydroxy-5β-cholan-24-oic) acids.
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2.2. Girard P (GP)-Derivatisation of 3-Oxo Groups
Previous studies have shown that hydrazone formation is very efficient towards 3-oxo-4-ene
substrates and to other α,β-unsaturated ketones [40,41,49,50]. In earlier EADSA studies using
cholesterol oxidase in phosphate buffer to convert 3β-hydroxy-5-ene sterols to their 3-oxo-4-ene
equivalents, GP derivatization was achieved by simply adding methanol to the incubation solution to
give a 70% methanol solution and then adding acetic acid and GP hydrazine reagent [40,41,45,46,50–52].
However, the buffer required for 3α-HSD oxidation of the 3α-hydroxy group to the 3-one is 100 mM
pyrophosphate buffer, pH 8.9, and upon methanol addition, necessary for subsequent hydrazone
formation, a precipitate is formed. This can be avoided by limiting the methanol content to 5%,
however, under these conditions hydrazone formation is reversed back to the hydrazine and free
carbonyl. For this reason, following incubation with 3α-HSD, samples were desalted on an Oasis
HLB reversed-phase column and eluted in methanol, a solvent suitable for subsequent GP hydrazone
formation. The GP derivatization efficiency was assessed by LC-MS in the negative-ion mode by
comparing the amount of underivatized oxidized acid present before and after the GP derivatization
step and incorporating the data into Equation (2).
Derivatization efficiency (%) = 100% − [(amount underivatized acid after
derivatization/amount underivatized acid before derivatization) × 100%] (2)
Unlike 3-oxo-4-ene sterols, which are derivatized with 100% efficiency in acidic
methanol [40], the derivatization efficiency for the 3-oxo-5β-hydrogen compounds formed
from their 3α-hydroxy-5β-hydrogen substrates (cholic, chenodeoxycholic, deoxycholic acids
and CA-3α,7α,12α-triol), was only 45–60%. Taurine- and glycine-conjugated cholic acid gave a
similar degree of derivatization efficiency after 3α-HSD oxidation. Despite the moderate yield of
derivatization products, the high sensitivity provided by GP derivatization of unconjugated substrates
(see Section 2.3.) negates this imperfection.
2.3. LC-MS Analysis of Oxidised/Derivatised 3α-Hydroxy-5β-Hydrogen Substrates
In this preliminary study we have not optimized the chromatographic or MS conditions for
the GP-derivatized target compounds but rather used existing LC-MS conditions used previously
for GP-derivatized sterols [44–46,52]. The logic behind this is that by using isotope-labelled GP
reagent, the ultimate aim will be to analyze sterols oxidized with cholesterol oxidase or 3α-HSD in
a single LC-MS run. Neither have we performed detailed investigations of limits of quantification
or linearity of dynamic range in the current study. However, we find that the sensitivity obtained
here for 3α-HSD oxidized/GP-derivatized C27 sterols with a 3α-hydroxy-5β-stereochemistry is of
the same order of magnitude to that obtained for GP derivatives generated after cholesterol oxidase
treatment of 3β-hydroxy-5-ene substrates. For the C27 substrates an on-column limit of detection (LOD,
signal/noise, 5:1) of 250 fg was achieved. The on-column LOD for the C24 acid, cholic acid, was 250 pg.
More work is required to explain this discrepancy in sensitivity and the even poorer sensitivity with
glycine- and taurine-conjugated acids. Optimization of the ion-source conditions for different groups
of analytes, or at least compromise in the settings chosen, is likely to be necessary.
2.4. MSn Fragmentation
A major driver for the current study was the poor fragmentation properties of unconjugated C24 and
C27 bile acids under conditions of ESI–tandem MS (MS/MS) at low collision energy (<100 eV) [5,53–56]
(see also MassBank of North America http://mona.fiehnlab.ucdavis.edu/). This has led to many studies
in which the precursor ion at unit mass resolution is also used as the “product ion” for generation of
LC–multiple reaction monitoring (MRM) chromatograms. Once derivatized with the GP reagent, both
bile acids and bile alcohols fragment under low-energy conditions with the loss of the pyridine group,
resulting in [M-Py]+ ions (see Scheme 1). These ions can be fragmented further in ion-trap instruments to
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give multistage fragmentation (MS3, [M]+→[M-Py]+→) spectra rich in fragment ions. The advantage of
MS3 is that it provides an extra dimension of separation compared to MS2, where spectra are a composite
of fragment ions derived from desired and undesired coselected precursor ions.
2.4.1. Triols and Tetrols
Shown in Figure 1 are representative reconstructed-ion chromatograms (RICs) and MS3
([M]+→[M-Py]+→) spectra of oxidized/GP-derivatized C27 bile alcohols 5β-cholestane-3α,7α,12α-triol
(C-3α,7α,12α-triol) and 5β-cholestane-3α,7α,12α,26-tetrol (C-3α,7α,12α,26-tetrol)), the C27 acid
(CA-3α,7α,12α-triol), and the C24 trihydroxy bile acid (cholic acid).
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from mass spectra recorded in the Orbitrap mass analyzer at a resolution of 120,000 (FWHM definition 
at m/z 400), with an m/z window of ± 5 ppm. MS3 spectra were generated in the linear ion-trap and 
recorded at the ion-trap detector of the Orbitrap-Elite mass spectrometer. Mass accuracy for fragment 
ion measurements made with the linear ion-trap is typically ± 0.3 Da. Postulated compositions of 
fragment ions are listed in Table 1. Note that the data for cholic acid was generated on an earlier 
version of instrument (i.e., Orbitrap-LTQ) at lower resolution and with reduced mass accuracy. 
The MS3 spectra show considerable similarity, with many fragment ions in the spectrum of the 
C26 acid and tetrol being shifted by m/z 30 and m/z 16, respectively from the corresponding triol. This 
is explained by the introduction of a carboxylic acid group (+ O2 − H2) or hydroxy (+ O) group to the 
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([M]+→[M-Py]+→) spectra of oxidized/GP-derivatized 3α-hydroxy-5β-bile alcohols and acids:
(a,b) C-3α,7α,12α-triol; (c,d) C-3α,7α,12α,26-tetrol; (e,f) CA-3α,7α,12α-triol; (g,h) cholic acid. The
RICs were generated from mass spectra recorded in the Orbitrap mass analyzer at a resolution of
120,000 (FWHM definition at m/z 400), with an m/z window of ± 5 ppm. MS3 spectra were generated
in the linear ion-trap and recorded at the ion-trap detector of the Orbitrap-Elite mass spectrometer.
Mass accuracy for fragment ion measurements made with the linear ion-trap is typically ± 0.3 Da.
Postulated compositions of fragment ions are listed in Table 1. Note that the data for cholic acid was
generated on an earlier version of instrument (i.e., Orbitrap-LTQ) at lower resolution and with reduced
mass accuracy.
The MS3 spectra show considerable similarity, with many fragment ions in the spectrum of the
C26 acid and tetrol being shifted by m/z 30 and m/z 16, respectively from the corresponding triol. This
is explained by the introduction of a carboxylic acid group (+ O2 − H2) or hydroxy (+ O) group to
the terminal carbon (C-26) of the sterol side-chain (Scheme 2). Postulated structures of fragment ions
for C-3α,7α,12α-triol are shown in Scheme 3 and for C-3α,7α,12α,26-tetrol and CA-3α,7α,12α-triol in
Supplemental Schemes S1 and S2, and are listed in Table 1.
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[M]+ [M]+ 552.4160 559.4599 568.4109 584.4058 582.3901 540.3432
[M-79]+ [M-Py]+ 473.3738 480.4177 489.3687 505.3636 503.3479 461.3010
[M-79-18]+ [M-Py-H2O]+ 455.3632 462.4071 471.3581 487.3530 485.3373 443.2904
[M-79-28]+ [M-Py-CO]+ 445.3789 452.4228 461.3738 477.3687 475.3530 433.3061
[M-79-36]+ [M-Py-(H2O)2]+ 437.3526 444.3965 453.3475 469.3424 467.3267 425.2798
[M-79-28-18]+ [M-Py-CO-H2O]+ 427.3683 434.4122 443.3632 459.3581 457.3424 415.2955
[M-79-36-18]+ [M-Py-(H2O)3]+ 419.3421 426.3860 435.3370 451.3319 449.3162 407.2693
[M-79-28-18-15]+ [M-Py-CO-H2O-NH]+ 412.3574 419.4013 428.3523 444.3472 442.3315 400.2846
[M-79-28-18-17]+ [M-Py-CO-H2O-NH3]+ 410.3417 417.3856 426.3366 442.3315 440.3158 398.2689
[M-79-28-36]+ [M-Py-CO-(H2O)2]+ 409.3577 416.4016 425.3526 441.3475 439.3318 397.2849
[M-79-36-36]+ [M-Py-(H2O)4]+ 401.3315 408.3754 417.3264 433.3213 431.3056 389.2587
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[M-79-28-36-15]+ [M-Py-CO-(H2O)2-NH]+ 394.3468 401.3907 410.3417 426.3366 424.3209 382.2740
[M-79-28-36-17]+ [M-Py-CO-(H2O)2-NH3]+ 392.3312 399.3751 408.3261 424.3210 422.3053 380.2584
[M-79-28-36-18]+ [M-Py-CO-(H2O)3]+ 391.3472 398.3911 407.3421 423.3370 421.3213 379.2744
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[M-79-28-36-15-18]+ [M-Py-CO-(H2O)3-NH]+ 376.3363 383.3802 392.3312 408.3261 406.3104 364.2635
[M-79-28-36-17-18]+ [M-Py-CO-(H2O)3-NH3]+ 374.3206 381.3645 390.3155 406.3104 404.2947 362.2478
[M-79-28-36-15-31]+ [M-Py-CO-(H2O)2-NH-CH2NH3]+ 363.3046 370.3485 379.2995 395.2944 393.2787 351.2318
[M-79-28-36-15-36+2]+ [M-Py-CO-(H2O)4-NH+H2]+ 360.3414 367.3853 376.3363 392.3312 390.3155 348.2686
[M-79-28-36-15-31-18]+ [M-Py-CO-(H2O)3-NH-CH2NH3]+ 345.2941 352.3380 361.2890 377.2839 375.2682 333.2213
M-79-28-36-15-31-36]+ [M-Py-CO-(H2O)4-NH-CH2NH3]+ 327.2835 334.3274 343.2784 359.2733 357.2576 315.2107
[A3+H-36]+ [A3+H-(H2O)2]+ 313.2890 320.3329 329.2839 345.2788 343.2631 301.2162
[A3-H-36]+ [A3-H-(H2O)2]+ 311.2733 318.3172 327.2682 343.2631 341.2474 299.2005
[A3-H-36-18]+ [A3-H-(H2O)3]+ 293.2628 300.3067 309.2577 325.2526 323.2369 281.1900
[A3-H-26]+ 285.2577 292.3016 301.2526 317.2475 315.2318 273.1849
[A3-H-36-36]+ [A3-H-(H2O)4]+ 275.2522 282.2961 291.2471 307.2420 305.2263 263.1794
[ABCD-∆x5-H]+ 249.1638 249.1638 249.1638 249.1638 249.1638 249.1638
[ABC-∆x5-H]+ 209.1325 209.1325 209.1325 209.1325 209.1325 209.1325
Note: m/z values are calculated for the chemical compositions. ABCD corresponds to the intact ring structure
including C-19 and C-18. ABC corresponds to the intact ring structure including C-19. ∆x5 corresponds to 5 double
bonds. The fragmenation-route A3 is depicted in the inset to Scheme 3. Colour Code: Red, loss of H2O; green, loss
of CO; blue, loss of NH or NH3; purple, loss of CH2NH3.
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When a hydroxy group is positioned at C-25 rather than C-26, the lability of the
hydroxy group leads to a more intense [M-Py-18]+ than [M-Py]+ ion in the MS2 ([M]+→)
spectrum of 5β-cholestane-3α,7α,12α,25-tetrol (C-3α,7α,12α,25-tetrol, Figure 2b) than in its epimer
C-3α,7α,12α,26-tetrol (Supplemental Figure S1b). See Table 1 to correlate m/z with fragment ion
composition. The MS3 ([M]+→[M-Py-18]+→) spectrum of C-3α,7α,12α,25-tetrol (Figure 2d) is almost
identical to the MS3 ([M]+→[M-Py]+→) of C-3α,7α,12α-triol (Figure 1b) but with an offset of m/z -2 (+
O – H2O, see also Supplemental Scheme S3).
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triol and C-3α,7α,12α,26-tetrol and the MS3 ([M]+→[M-Py-18]+→) spectrum of C-3α,7α,12α,26-tetrol 
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shows the same pattern of fragment ions as the C27 acid CA-3α,7α,12α-triol (Figure 1f) but offset by 
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[A3-H-(H2O)3]+ when an additional hydroxy group is at C-25, Table 1), a triply unsaturated carbonium 
ion consisting of B-, C- and D-rings plus the C17 side-chain, where charge is delocalized across the 
three double bonds in the ring system (Scheme 3, inset). An equivalent fragment ion is not observed 
in cholesterol oxidase-oxidized/GP-derivatized 3β,5α,6β-triols (Figure 3). 
Fig re 2. (a) RIC and (b) MS2 ([M]+→), (c) S3 ([ ]+→[M-Py]+→), (d) ([M]+→[M-Py-18]+→)
spectra of oxidized/GP-derivatized C-3α,7α,12α,25-tetrol. For comparison, MS2 ([M]+→) spectra
of C-3α,7α,12α-triol and C-3α,7α,12α,26-tetrol and the MS3 ([M]+→[M-Py-18]+→) spectrum of
C-3α,7α,12α,26-tetrol are shown in Supplemental Figure S1a–c respectively. Mass spectra recorded at
the peak of the RIC for these and other sterols analyzed are shown in Supplemental Figure S2. Data
was generated on the Orbitrap-Elite mass spectrometer as in Figure 1. See Table 1 to correlate m/z with
fragment ion composition.
Unsurprisingly, the MS3 ([M+→[M-Py]+→) spectrum of the C24 acid, cholic acid (Figure 1h),
shows the same pattern of fragment ions as the C27 acid CA-3α,7α,12α-triol (Figure 1f) but offset
by m/z -42 (-C3H6), corresponding to the mass difference between equivalent C27 and C24 acids
(cf. Supplemental Schemes S2 and S4).
A key structurally distinct fragment ion for all the 3α,7α,12α-triols is the [A3-H-(H2O)2]+ ion (or
[A3-H-(H2O)3]+ when an additional hydroxy group is at C-25, Table 1), a triply unsaturated carbonium
ion consisting of B-, C- and D-rings plus the C17 side-chain, where charge is delocalized across the
three double bonds in the ring system (Scheme 3, inset). An equivalent fragment ion is not observed in
cholesterol oxidase-oxidized/GP-derivatized 3β,5α,6β-triols (Figure 3).
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2.4.2. Pentols
The human autosomal recessive disease, cerebrotendinous xanthomatosis (CTX), results from a
deficiency in cytochrome P450 27A1 (CYP27A1) [57], a key enzyme in the conversion of cholesterol to
bile acids [28,29]. As a consequence of this deficiency, polyhydroxy-bile alcohols are produced [58,59],
providing an alternative route for bile acid biosynthesis and cholesterol removal [60].
As with C-3α,7α,12α,25-tetrol, the presence of a labile 25-hydroxy group in the
epimers 5β-cholestane-3α,7α,12α,24R,25-pentol (C-3α,7α,12α,24R,25-pentol) and 5β-cholestane-
3α,7α,12α,24S,25-pentol (C-3α,7α,12α,24S,25-pentol) results in abundant [M-Py-18]+ ions in the MS2
([M]+→) spectra, and the MS3 ([M]+→[M-Py-18]+→) spectra resembles the MS3 ([M]+→[M-Py]+→)
spectra of cholestane etrols but is offset by m/z -2 (+ O – H2O) (Figure 4). Althoug the MSn spectra
are very similar, the two epimers are re ily separat d on the LC column. Here in the MS2 ([M →)
and MS3 ([M]+→[M-Py]+) spectra, in addition to the [A3-H-(H2O)2]+ fragment ion, a [A3-H-(H2O)3]+
fragment ion is also prominent (See Table 1 to correlate m/z with fragment ion composition).
Movement of the hydroxy group from C-24 to C-26 as in 5β-cholestane-3α,7α,12α,25,26-pentol
(C-3α,7α,12α,25,26-pentol) results in a small delay in retention time and subtle changes to the
MS2 ([M]+→) and MS3 ([M]+→[M-Py]+→ and [M]+→[M-Py-18]+→) spectra, for example, reduced
abundance of fragment ions having lost four water molecules compared the equivalent having
lost three water molecules (i.e., [M-79-36-36]+/[M-79-36-18]+) (Figure 5b–d, cf. Figure 4b–d,f–h).
The bile alcohol 5β-cholestane-3α,7α,12α,26,27-pentol (C-3α,7α,12α,26,27-pentol) elutes between the
24R- and 25S-epimers of C-3α,7α,12α,24,25-pentol, but gives very different MSn spectra to the other
cholestanepentols on account of the absence of a labile C-25-hydroxy group (Figure 5f–h, Supplemental
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Scheme S6). This is reflected in the ratio of fragment ions [M-79-36-18]+/[M-79-36]+ which is greatly
reduced compared to pentols with a 25-hydroxy group. The comparative stability of the primary
hydroxy groups at the termini, C-26 and C-27, is further reflected by an absence of fragment ions
having lost four water molecules (e.g., [M-79-36-36]+).
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Figure 4. LC–(MS)MSn analysis xidized/GP-derivatized C-3α,7α,12α,24R,25-pentol and
C-3α,7α,12α, 4S,25-pentol: (a) RIC, (b) MS2 ([ ]+→), (c) MS3 ([M]+→[M-Py]+→), and
(d) ([M] [M-Py-18]+→) from the analysis of C-3α,7α,12α,24R,25-pentol. (e) RIC, (f) MS2
([M]+→), (g) MS3 ([M]+→[M-Py]+→), and (h) ([M]+→[M-Py-18]+→) from the analysis of
C-3α,7α,12α,24S,25-pentol. Data was generated on the Orbitrap-Elite mass spectrometer as in Figure 1.
Fragment ions are described in Table 1 and postulated structures are shown in Scheme 4.
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Movement of the hydroxy group from C-24 to C-26 as in 5β-cholestane-3α,7α,12α,25,26-pentol 
(C-3α,7α,12α,25,26-pentol) results in a small delay in retention time and subtle changes to the MS2 
([M]+→) and MS3 ([M]+→[M-Py]+→ and [M]+→[M-Py-18]+→) spectra, for example, reduced 
abundance of fragment ions having lost four water molecules compared the equivalent having lost 
three water molecules (i.e., [M-79-36-36]+/[M-79-36-18]+) (Figure 5b–d, cf. 4b–d, 4f–h). The bile alcohol 
5β-cholestane-3α,7α,12α,26,27-pentol (C-3α,7α,12α,26,27-pentol) elutes between the 24R- and 25S-
epimers of C-3α,7α,12α,24,25-pentol, but gives very different MSn spectra to the other 
cholestanepentols on account of the absence of a labile C-25-hydroxy group (Figure 5f–h, 
Supplemental Scheme S6). This is reflected in the ratio of fragment ions [M-79-36-18]+/[M-79-36]+ 
which is greatly reduced compared to pentols with a 25-hydroxy group. The comparative stability of 
the primary hydroxy groups at the termini, C-26 and C-27, is further reflected by an absence of 
fragment ions having lost four water molecules (e.g., [M-79-36-36]+). 
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Figure 5. LC–(MS)MSn anal oxidized/GP-derivatized C-3α,7α,12α,25,26-pe tol and
C-3α,7 ,12α,26,27-pentol: (a) RIC, (b) MS2 [M]+→), (c) MS3 ([M]+→[M-Py]+→), and
(d) ([M]+→[M-Py-18]+→) from the analysis of C-3α,7α,12α,25,26-pentol. (e) RIC, (f) MS2
([M]+→), (g) MS3 ([M]+ [M-Py]+ ), and (h) ([M]+→[M-Py-18]+→) from the analysis of
C-3α,7α,12α,26,27-pentol. Data was generated on the Orbitrap-Elite mass spectrometer as in Figure 1.
Fragment ions are described in Table 1 and postulated structures are shown in Supplemental
Schemes S5 and S6.
Molecules 2019, 24, 597 14 of 20
Although it co-elutes with C-3α,7α,12α,24S,25-pentol, 5β-cholestane-3α,7α,12α,23,25-pentol
(C-3α,7α,12α,23,25-pentol) gives unique MSn spectra (Figure 6). Each of the MS2 ([M]+→), MS3
([M]+→[M-Py]+→) and MS3 ([M]+→[M-Py-18]+→) spectra show an unusual pattern of fragment ions
at m/z 431.3, 413.3, and 395.3. It is not immediately obvious why this triad of fragment ions is so
distinct for this molecule. Neither are the structures or chemical compositions of all these fragments
easy to reconcile with the MS3 ([M]+→[M-Py-18]+→) spectrum.
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Figure 6. LC–(MS)MSn analysis of oxidized/GP-derivatized C-3α,7α,12α,23,25-pentol. (a) RIC, (b) MS2
([M]+→), (c) MS3 ([M]+→[M-Py]+→), and (d) ([M]+→[M-Py-18]+→). Data was generated on the
Orbitrap-Elite mass spectrometer as in Figure 1. Fragment ions are described in Table 1 and postulated
structures are shown in Supplemental Schemes S7.
3. Discussion
In this communication we describe preliminary studies to develop an enzyme-assisted
derivatization for C27 bile alcohols and acids with a 3α-hydroxy-5β-hydrogen stereochemistry. The
method still requires further optimization, particularly with respect to the GP-derivatization step
which only gave a 45%–60% yield. Despite this, the considerable sensitivity of GP-derivatives makes
the moderate yield tolerable. Although the LC-MS sensitivity for detection of C24 acids was not
as good as for C27 acids, the rich MS3 fragment ion spectra provide a significant advantage over
conventional MS/MS spectra of unconjugated acids where few fragment ions are observed. The
on-column detection limit of 250 fg for C27 analytes translates to a limit of detection of about 0.2 ng/mL
if 100 µL of biological fluid is worked up and 1% injected on-column, as in our usual procedure with
EADSA [52]. For comparison, Johnson et al. could measure CA-3α,7α,12α-triol, after derivatization
to the dimethylaminoethyl ester, at a concentration of about 60 ng/mL in as little as 5 µL of plasma,
with 20% injected-on column [38], while DeBarber et al. determined the limit of quantification of
7α,12α-dihydroxy-5β-cholestan-3-one, the 3-oxo form of C-3α,7α,12α-triol, to be 20 ng/mL from 4 µL
of plasma after derivatization to the oxime with (O-(3-trimethylammoniumpropyl) hydroxylamine)
bromide [39]. We have not yet rigorously tested the repeatability of the EADSA methodology in
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biological samples. This will become relevant with the availability of isotope-labelled standards, which
can be synthesized by methods described by Johnson et al. and by Shoda et al. [61]. Isotope-labelled
internal standards will similarly facilitate the progression of the method to a quantitative format. We
did not attempt to optimize LC-MS conditions for the GP-derivatives analyzed in this study; instead
we used previously optimized conditions for derivatized oxysterols. The logic behind this was to
allow the expansion of our sterol profiling method to include bile acids and alcohols derivatized with
[2H0]GP after 3α-HSD treatment and oxysterols, and cholestenoic and cholenoic acids derivatized
with [2H5]GP after cholesterol oxidase treatment, or vice versa, in a single LC-MS run. At present there
are challenges with this strategy, as efficient ionization of glycine- and taurine-conjugated bile acids
requires different ion-source conditions from the unconjugated GP-derivatives.
4. Materials and Methods
4.1. Materials
CA-3α,7α,12α-triol (LMST04030001) and [2H7]C-3β,5α,6β-triol were from Avanti
Polar Lipids (Alabaster, AL, USA). Bile alcohols, C-3α,7α,12α-triol (LMST04030035),
C-3α,7α,12α,25-tetrol (LMST04030037) and C-3α,7α,12α,26-tetrol, (LMST04030159 or LMST04030160),
C-3α,7α,12α,24R,25-pentol (LMST04030177), C-3α,7α,12α,24S,25-pentol (LMST04030039),
C-3α,7α,12α,25,26-pentol (LMST04030016), 3α,7α,12α,26,27-pentol (LMST04030041) and
C-3α,7α,12α,23,25-pentol (LMST01010240 or LMST01010241) were kind gifts from Professor
Jan Sjövall, Karolinska Institutet, Stockholm. BA-3β,5α,6β-triol (LMST04010339) was a kind gift from
Professor Douglas Covey, Washington University. Other C24 bile acids were from Sigma-Aldrich
(Dorset, UK) or Fluka Chemie (Buchs, Switzerland). 3α-Hydroxysteroid dehydrogenase (3α-HSD)
from Pseudomonas testosteroni was from Sigma-Aldrich (Dorset, UK). β-Nicotinamide adenine
dinucleotide hydrate and sodium pyrophosphate decahydrate were from Sigma-Aldrich. [2H0]GP
([1-(carboxymethyl)pyridinium chloride hydrazide]) reagent was from TCI Europe (Oxford, UK).
[2H5]GP reagent was synthesized as the bromide salt as described in Crick et al. [45]. Solid phase
extraction (SPE) columns, certified Sep-Pak C18, 200 mg (3 cm3), and 60 mg Oasis HLB (3 cm3), were
from Waters Inc. (Elstree, UK). Solvents were obtained from Fisher Scientific (Loughborough, UK).
Acetic acid and formic acid were of AnalaR NORMAPUR grade (BDH, VWR, Lutterworth, UK).
4.2. Methods
4.2.1. Oxidation and Derivatization
Oxidation of analytes by 3α-HSD was essentially as described by Une et al. [48]. β-NAD+ hydrate
(19.8 mg) was dissolved in 100 mM pyrophosphate buffer pH 8.9 (1 mL). Analyte (40–400 ng) dissolved
in ethanol (10 µL) was added to the buffered solution giving a final concentration of 1% ethanol,
followed by addition of 3α-HSD (0.06 units). After incubation at room temperature for 20 h, methanol
(40 µL) was added (giving an organic content of 5%). To separate oxidized analyte from buffer,
the solution was loaded onto a HLB column (60 mg, previously washed with methanol, 6 mL, and
conditioned with 5% methanol, 6 mL) followed by a rinse with 5% methanol (0.5 mL). The column
was then further washed with 5% methanol (6 mL). Analytes were eluted with methanol (2 mL). For
samples to be analyzed by ESI in the negative-ion mode, to monitor oxidation efficiency, the methanol
eluate was diluted with water to give a 60% methanol solution and was analyzed by LC-MS on the
Orbitrap-Elite high resolution mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) at
120,000 resolution (full width at half maximum height at m/z 400). To derivatize samples with GP
reagent, glacial acetic acid (150 µL) was added followed by GP reagent (150 mg chloride salt, 190 mg
bromide salt) and the mixture was left at room temperature overnight. The next day, water (1 mL) was
added immediately prior to a second SPE step. This second SPE step was performed with recycling
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on an Oasis HLB column (60 mg) to remove excess derivatization reagent and was carried out as
described in Abdel-Khalik et al. [52].
4.2.2. LC-MS(MSn) Analysis
LC-MS(MSn) was performed in the positive-ion mode as described in Abdel-Khalik et al. utilizing
the Orbitrap-Elite hybrid MS preceded by a Dionex Ultimate 3000 LC system (Dionex, now Thermo
Fisher Scientific) [52]. For analysis of underivatized acids in the negative-ion mode, other than for
polarity reversal and a change of column from a Hypersil Gold C18 to a Kinetex core-shell technology
XB-C18 column (2.6 µm, 2.1 mm × 50 mm, Phenomenex, Macclesfield, UK), the method was as for
positive-ion mode LC-ESI-MS(MSn) as described in Abdel-Khalik et al. [52].
5. Patents
The derivatization method described in this manuscript is patented by Swansea University
(US9851368B2) and licensed by Swansea Innovations to Avanti Polar Lipids and to Cayman
Chemical Company.
Supplementary Materials: The following are available online. Supplemental Figure S1. MS2
([M]+→) spectra of (a) C-3α,7α,12α-triol and (b) C-3α,7α,12α,26-tetrol, and (c) MS3 ([M]+→[M-Py-18]+→)
spectrum of C-3α,7α,12α,26-tetrol. Data were generated on the Orbitrap-Elite mass spectrometer
as in Figure 1. Supplemental Figure S2. Mass spectra of oxidized/GP-derivatized bile alcohols
and acids recorded at the peak of their chromatographic elution. Except for C-3α,7α,12α,26-tetrol,
C-3α,7α,12α,25,26-pentol, C-3α,7α,12α,26,27-pentol and C-3α,7α,12α,23,25-pentol which were injected (35 µL)
on-column at 0.2 pg/µL all other analytes were inject on-column at 2 pg/µL. (a) C-3α,7α,12α-triol,
(b) C-3α,7α,12α,26-tetrol, (c) CA-3α,7α,12α-triol, (d) C-3α,7α,12α,25-tetrol, (e) [2H7]C-3β,5α,6β-triol,
(f) BA-3β,5α,6β-triol, (g) C-3α,7α,12α,24R,25-pentol, (h) C-3α,7α,12α,24S,25-pentol, (i) C-3α,7α,12α,25,26-pentol,
(j) C-3α,7α,12α,26,27-pentol and (k) C-3α,7α,12α,23,25-pentol. Data were generated on the Orbitrap-Elite
mass spectrometer as in Figure 1. Scheme S1: MS2 and MS3 fragmentation of oxidized/GP derivatized
C-3α,7α,12α,26-tetrol. For simplicity the fragmented Girard derivatizing group is shown in its linear isomeric
form. Cyclic forms are depicted in Scheme 1. Scheme S2: MS2 and MS3 fragmentation of oxidized/GP derivatized
CA-3α,7α,12α-triol. For simplicity the fragmented Girard derivatizing group is shown in its linear isomeric form.
Cyclic forms are depicted in Scheme 1. Scheme S3: MS2 and MS3 fragmentation of oxidized/GP derivatized
C-3α,7α,12α,25-tetrol. For simplicity the fragmented Girard derivatizing group is shown in its linear isomeric
form. Cyclic forms are depicted in Scheme 1. Scheme S4: MS2 and MS3 fragmentation of oxidized/GP derivatized
BA-3α,7α,12α-triol. For simplicity the fragmented Girard derivatizing group is shown in its linear isomeric form.
Cyclic forms are depicted in Scheme 1. Scheme S5: MS2 and MS3 fragmentation of oxidized/GP derivatized
C-3α,7α,12α,25,26-pentol. For simplicity the fragmented Girard derivatizing group is shown in its linear isomeric
form. Cyclic forms are depicted in Scheme 1. Scheme S6: MS2 and MS3 fragmentation of oxidized/GP derivatized
C-3α,7α,12α,26,27-pentol. For simplicity the fragmented Girard derivatizing group is shown in its linear isomeric
form. Cyclic forms are depicted in Scheme 1. Scheme S7: MS2 and MS3 fragmentation of oxidized/GP derivatized
C-3α,7α,12α,23,25-pentol. For simplicity the fragmented Girard derivatizing group is shown in its linear isomeric
form. Cyclic forms are depicted in Scheme 1.
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